Puma Biotechnology Inc (PBYI) Stock AnalysisPBYIStock AnalysisPuma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Puma Biotechnology Inc is currently priced at $9.06, which is above the analyst target of $6, indicating potential overvaluation. The stock has shown a year-to-date increase of 57.02%, but recent insider selling has surged by 230.93%, suggesting caution. Additionally, the RSI is at 49.23, indicating a neutral momentum. Given these factors, it may be wise to hold rather than buy at this time.

9 analysts cover PBYI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.50.